

Simplified Prescription of Diabetes Technology and Medications

CONTRIBUTING AUTHORS: Colin Crowe, MD, Case Western Reserve University; Noha Elnagar, MD, MSBS, PA-C, University of Toledo; Kathleen Dungan, MD, MPH, The Ohio State University, behalf of Team Best Practices



In Spring 2021, the Ohio Department of Medicaid (ODM) launched its *Preferred Diabetic Supply List*, consolidating six unique lists previously dictated by each managed care plan into one.¹ The initiative mirrored the successful rollout of ODM's *Unified Preferred Drug List* in 2020.²

This represents an important and potentially transformational shift for diabetes care, simplifying clinicians' prescription of technology and medications to help patients reach glycemic targets and diabetes goals.

While metformin remains a first-line therapeutic option, the 2022 Standards recommend therapeutic choices based on comorbidities as well as patient-centered factors, such as cost and access (Table 1).^{2,3}

Diabetes technology is defined as the devices and systems people with diabetes use to manage their condition, including test strips, glucometers, and continuous glucose monitors.⁴ Obtaining and correctly using a home glucose monitoring device is a key part of comprehensive management of diabetes by patients and clinicians. Choice of monitoring device should be individualized based on patient factors and should align with patient goals for care (Table 2).⁴

Medication intensification, in addition to lifestyle modification, glucose monitoring, and **Diabetes Self-Management Education and Support**, may help patients reach glycemic targets. When choosing individual medication treatment, insurance coverage, benefits, side effects and route of administration should be considered.^{2,4}

Access **Cardi-OH's evidence-based tools** and resources to learn more about the care of patients with diabetes.

Table 1. 2022 Ohio Medicaid Preferred Diabetes Formulary As of July 2022

Drug Class	Preferred
Non-Insulin	
Metformin and combination	Actoplus Met XR (pioglitazone/metformin), glipizide/metformin, glyburide/metformin, Invokamet (canagliflozin/metformin), Janumet (sitagliptin/metformin), Janumet XR, Jentadueto (linagliptin/metformin), metformin, metformin ER (generic of Glucophage XR), pioglitazone/metformin, repaglinide/metformin, Synjardy (empagliflozin/metformin)
Sulphonylurea SFU	glimepiride, glipizide, glyburide
Glucagon-like peptide-1 receptor agonist GLP-1 RA	Byetta (exenatide), Trulicity (dulaglutide), Victoza (liraglutide)
Sodium-glucose cotransporter-2 inhibitor SGLT2i	Farxiga (dapagliflozin), Invokana (canagliflozin), Jardiance (empagliflozin)
Dipeptidyl peptidase-4 inhibitor DPP-4i	Januvia (sitagliptin), Tradjenta (linagliptin)
Thiazolidinedione TZD	pioglitazone
Alpha glucosidase inhibitor AGI	acarbose, miglitol
Glinide	nateglinide, repaglinide
Insulin	
Basal	Lantus (glargine), Levemir (detemir), Toujeo (glargine U-300), Tresiba (degludec) ⁵
Bolus	Apidra (glulisine), aspart, Humalog (lispro) U-100, Humulin R (regular insulin) U-500, lispro, Novolog (aspart) U100
Premix	Humalog 50/50 (lispro protamine/lispro), Humalog 75/25 (lispro protamine/lispro), Humulin 70/30 (insulin isophane/regular insulin), aspart protamine/aspart, Novolog 70/30 (aspart protamine/aspart)

⁵ Step therapy

Table 2. 2022 Ohio Medicaid Preferred Diabetic Supply List As of July 2022

Supplies	Preferred
Blood glucose meters	OneTouch UltraMini, OneTouch Ultra 2, OneTouch Verio, OneTouch Verio Flex, OneTouch Verio IQ, OneTouch Verio Reflect, ReliOn True Metrix Air, True Metrix, True Metrix Air
Continuous glucose monitors	DexCom G6 Transmitter/Sensor/Receiver, FreeStyle Libre 2 Sensor/Reader, FreeStyle Libre 14-Day Sensor/Reader, FreeStyle 3 Receiver
Test strips	OneTouch Ultra Blue, OneTouch Verio, ReliOn True Metrix, True Metrix
External diabetes devices	Omnipod 5 Pack Pods, Omnipod Dash 5 Pack Pods, Omnipod Dash Intro Kit, Omnipod 5 G6 Intro Kit, Omnipod 5 G6 5 Pack Pods, V-GO 40, V-GO 30, V-GO 20

References

- Ohio Department of Medicaid. 2022 Preferred Diabetic Supply List. https://pharmacy.medicaid.ohio.gov/sites/default/files/OH_July_2022_PDSL.pdf#overlay-context=drug-coverage. Published July 1, 2022. Accessed July 8, 2022.
- Ohio Department of Medicaid. 2022 Unified Preferred Drug List. https://pharmacy.medicaid.ohio.gov/sites/default/files/20220701_UPDL_FINAL.pdf#overlay-context=unified-pdl. Published July 1, 2022. Accessed July 8, 2022.
- American Diabetes Association Professional Practice Committee, Draznin B, Aroda VR, et al. 9. Pharmacologic Approaches to glycemic treatment: standards of medical care in diabetes-2022. *Diabetes Care*. 2022 Jan 1;45(Suppl 1):S125-S143. doi: 10.2337/dc22-S009.
- American Diabetes Association Professional Practice Committee, Draznin B, Aroda VR, et al. 7. Diabetes technology: standards of medical care in diabetes-2022. *Diabetes Care*. 2022 Jan 1;45(Suppl 1):S97-S112. doi: 10.2337/dc22-S007.

The Ohio Cardiovascular and Diabetes Health Collaborative is funded by the Ohio Department of Medicaid and administered by the Ohio Colleges of Medicine Government Resource Center. The views expressed in this document are solely those of the authors and do not represent the views of the state of Ohio or federal Medicaid programs.

For more information head to Cardi-OH.org.

Update of *Capsule 16* (August 2021)

© 2022 Cardi-OH